Dermatology

The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.

The US biotech has upsized its public offering to $175m after the success of soquelitinib in a very early trial for atopic dermatitis.

The inflammatory skin disease typically affects the anogenital area and the Denmark-headquartered firm has started a Phase III trial evaluating its chronic hand eczema in that space.

Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.

Sun launches tildrakizumab, its star psoriasis therapy in India seven years after US FDA approval at what’s seen as a carefully calibrated price point. Can it ruffle entrenched products like secukinumab?

The European Medicines Agency has begun evaluating the EU marketing applications for a new batch of drugs, including products from Incyte, Sanofi and Novo Nordisk that target hidradenitis suppurativa, rabies and hemophilia A, respectively.

While the European Medicines Agency’s human medicines committee voted in favor of EU approval for 10 new products, it reaffirmed its previous decision not to grant Aqneursa new active substance status.

Daily Niagen use increased NAD+ levels for subjects in long-COVID study, showing “encouraging within-group improvements” in fatigue, sleep and mood. Tru Niagen Beauty is “cellular-first formula designed to support skin elasticity and the appearance of hair, skin, and nails.”

Sales of Zoryve comfortably exceeded consensus in the third quarter and both the foam and cream formulations are selling well across its dermatological indications.

The US biotech has raised $300m to advance its atopic dermatitis candidate towards Phase III trials next year.

The Swiss group is more than holding its own against Dupixent for prurigo nodularis and is looking to make further inroads into Sanofi and Regeneron's blockbuster's market share in atopic dermatitis.

Celltrion has won the race to launch the first biosimilar to Novartis/Roche’s blockbuster treatment for chronic spontaneous urticaria and severe persistent allergic asthma in Europe.